user
menu
letter
Sign InRegister
langEnglisharrow

Monoclonal Anti-Adenoviruses AAV9 Neutralizing Antibody, Mouse IgG1 (28B9C5)

Cat. No. / Size
Price
Availability
Qty
AA9-Y2142-100ug
$400.00
In Stock - Delivery in 1-2 business days
AA9-Y2142-1mg
$2,770.00
In Stock - Delivery in 2-3 weeks
AA9-Y2142
Sub-Total :
$ 0
Customize Product Request Quote
Contact Us
Contact Us
Sub-Total:
$ 0
Request Quote
Product Details
Performance Data
Reviews & Citations
Resources
  • Product Details
  • Performance Data
  • Reviews & Citations
  • Important Statement
  • Resources
Source

Monoclonal Anti-Adenoviruses AAV9 Neutralizing Antibody, Mouse IgG1 (28B9C5) (Cat. No. AA9-Y2142) is a mouse monoclonal antibody produced from a hybridoma generated by fusion of SP2/0 myeloma cells with mouse B lymphocytes.

Antibody Type

Hybridoma Monoclonal

Clone

28B9C5

Isotype

Mouse IgG1, Kappa

Host Species

Mouse

Immunogen

AAV9

Application
Application
Recommended Use / Performance
ELISA
0.2-2 μg/mL
Cross Verification

This product can specially react with AAV9.
No reactivity to AAV1/ AAV2/ AAV3/ AAV5/ AAV6/ AAV8.

Purification

Protein A purified.

Concentration

Please refer to the Certificate of Analysis (CoA).

Form

Liquid

Formulation

Supplied a 0.22 μm-filtered solution in PBS (pH 7.4), with trehalose as protectant.

Please contact us for customized product forms or formulations.

Storage

Please avoid repeated freeze-thaw cycles.

This product is stable after storage at:
  • The product MUST be stored at -70°C or lower upon receipt;
  • -70°C for 12 months under sterile conditions.
Notices

Product Specific Notices: For research use only.

ACRO Quality Management System

Background

AAV9 (Adeno-Associated Virus Serotype 9) is a highly efficient and safe gene therapy vector belonging to the Parvoviridae family. It is characterized by broad tissue tropism, enabling efficient transduction of the heart, liver, skeletal muscle, central nervous system (with the ability to cross the blood-brain barrier), and retina, among others. Compared to other serotypes, AAV9 exhibits stronger systemic diffusion capacity and lower immunogenicity, reducing the risk of host immune rejection. Its single-stranded DNA genome (~4.7 kb) allows long-term stable expression of transgenes but has a limited packaging capacity (≤5 kb).
AAV9 has been utilized in clinical trials for various diseases, such as spinal muscular atrophy (SMA), Duchenne muscular dystrophy (DMD), and familial hypercholesterolemia.